Johnson & Johnson: Anemia trials

The registry lists 56 Anemia studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 2 27Phase 3 19Phase 4 4No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• An Observational Study to Predict the Response of Erythropoietin Treatment in Participants With Cancer Related Anemia Receiving ChemotherapyTerminatedNCT01736215Results posted
• A Safety Study of Epoetin Alfa in Patients With Cancer Who Have Chemotherapy-Related AnemiaCompletedNCT01394991Phase 4Results posted
• An Efficacy and Safety Study of Epoetin Alfa for Initiation and Maintenance Treatment of Patients With Anemia Associated With Chronic Kidney DiseaseCompletedNCT00440557Phase 3Results posted
• PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD PatientsCompletedNCT00440466Phase 3Results posted
• A Study Comparing Two Different PROCRIT Doses to a Dose of ARANESP in Anemic Cancer Patients Receiving ChemotherapyTerminatedNCT00386152Phase 2Results posted
• A Study of the Use of PROCRIT (Epoetin Alfa) for the Treatment of Anemia in People With Chronic Kidney Disease Who Live in Long-term Care Facilities.CompletedNCT00337935Phase 2Results posted
• Assess Functional Outcomes in Anemic, Critically Ill, Trauma Patients When Taking Epoetin AlfaTerminatedNCT00210626Phase 2Results posted
• National Cancer Institute Thai Cancer Anemia SurveyCompletedNCT01030159
• Thai Cancer Anemia Survey in Chulalongkorn HospitalCompletedNCT01018043
• The Effect of Epoetin Alfa on Cardiac Function and Quality of Life in Patients With Early Renal ((Kidney) DiseaseCompletedNCT00446576Phase 3
• Survey on the Treatment of Anemia Using Recombinant Human Erythropoietin 2 (STAR-2)CompletedNCT00398749
• PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation TherapyCompletedNCT00388336Phase 2
• A Study to Evaluate the Hematologic Response Rate (the Rate at Which the Hemoglobin Level Rises) of PROCRIT (Epoetin Alfa) Given at a Dose of 80,000 Units Once Weekly to Cancer Patients With Anemia Who Are Receiving Chemotherapy.CompletedNCT00341055Phase 3
• An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Three WeeksCompletedNCT00338416Phase 2
• Alternate Dosing of PROCRIT (Epoetin Alfa) in Patients With Cancer and Chemotherapy Induced AnemiaCompletedNCT00338299Phase 2
• An Efficacy and Safety Study of PROCRIT (Epoetin Alfa) in Cancer Patients Receiving Chemotherapy Every Week or Every Four WeeksCompletedNCT00337948Phase 2
• Effects of Early Correction of Anemia in Patients With Chronic Renal InsufficiencyTerminatedNCT00312871Phase 4
• A Study of PROCRIT (Epoetin Alfa) 80,000 Units (U) Once Every Four Weeks (Q4W) vs. 40,000 U Once Every Two Weeks (Q2W) in Cancer Patients Not Receiving ChemotherapyTerminatedNCT00306267Phase 2
• A Study of the Effectiveness and Safety of Treatment With Epoetin Alfa on Hemoglobin Levels, Red Blood Cell Transfusions, and Quality of Life in Patients With Cancer Receiving Platinum-containing ChemotherapyCompletedNCT00283465Phase 4
• A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in Patients With Acquired Immunodeficiency Syndrome (AIDS) Who Are Receiving Zidovudine (AZT) TherapyCompletedNCT00270283Phase 2
• A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo for the Treatment of Anemia in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused by the Disease and by Zidovudine (AZT) TherapyCompletedNCT00270270Phase 2
• A Study to Evaluate the Effectiveness and Safety of Epoetin Alfa During the Period When One is Donating One's Own Blood Before Surgery.CompletedNCT00270179Phase 3
• The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving ChemotherapyCompletedNCT00270166Phase 3
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Facilitating the Presurgical Collection of Blood to be Used for Self-donation During Surgery on the Spine, Hip, or Knee.CompletedNCT00270140Phase 3
• Epoetin Alfa for Anemia in Patients With Cancer Receiving Non-platinum ChemotherapyCompletedNCT00270127Phase 3
• A Study of the Safety and Effectiveness of Epoetin Alfa in Facilitating Self-donation of Blood Before Surgery in Patients Who Are Undergoing Orthopedic Surgery and Who Have Low Hematocrit Levels (the Percent of Red Blood Cells in Whole Blood)CompletedNCT00270114Phase 2/3
• The Effect of Epoetin Alfa on the Anemia of Patients With Multiple MyelomaCompletedNCT00270101Phase 3
• A Study to Determine Whether Epoetin Alfa Can Reduce the Need for Blood Transfusions in Patients During the Period of Time Around Major Orthopedic Surgery.CompletedNCT00270088Phase 3
• A Study to Evaluate the Safety of Epoetin Alfa and Its Effectiveness in Facilitating the Presurgical Collection of Blood From Anemic Patients for Possible Self-transfusion During and After Scheduled Joint Surgery.CompletedNCT00270062Phase 3
• Epoetin Alfa for the Treatment of Anemia Resulting From Chronic Lymphocytic LeukemiaCompletedNCT00270049Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS (Acquired Immunodeficiency Syndrome) Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their DiseaseCompletedNCT00270010Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia as a Result of Cancer Treatment With Cisplatin, a Platinum-containing Chemotherapy DrugCompletedNCT00269997Phase 2
• A Study to Determine the Safety and Effectiveness of Epoetin Alfa Versus Placebo in Patients With Persistent Anemia Caused by Advanced CancerCompletedNCT00269984Phase 2
• A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.WithdrawnNCT00269971Phase 3
• A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement SurgeryCompletedNCT00269958Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in AIDS Patients With Anemia Caused Both by Their Disease and by AZT (Zidovudine, an Antiviral Drug) Given as Treatment for Their DiseaseCompletedNCT00269945Phase 2
• A Study to Evaluate the Safety and Effectiveness of Epoetin Alfa in Patients With Anemia as a Result of Advanced Cancer and Treatment With Aggressive ChemotherapyCompletedNCT00266617Phase 2
• Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have AnemiaCompletedNCT00264108
• A Study of the Safety and Efficacy of Long-term Correction of Anemia With Epoetin Alfa in Early Hemodialysis PatientsCompletedNCT00261521Phase 3
• A Study to Assess the Effectiveness of PROCRIT (Epoetin Alfa) Dosing Every 2 Weeks Versus Once a Week in Anemic HIV-infected PatientsTerminatedNCT00246298Phase 2
• Treatment of Anemia in Diabetic Subjects With CKDTerminatedNCT00240734Phase 2
• Randomized, Double-blind, Placebo-controlled Study to Assess Fatigue in Patients With ACD Due to RA Receiving PROCRITTerminatedNCT00236678Phase 2
• PROCRIT and Short-Term Outcomes in Orthopedic SurgeryTerminatedNCT00236405Phase 2
• A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic AnemiaTerminatedNCT00228995Phase 2
• A Study of the Safety and Effectiveness of Epoetin Alfa on Hemoglobin Levels and Blood Transfusions in Cancer Patients Receiving ChemotherapyCompletedNCT00216541Phase 4
• A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.CompletedNCT00212875Phase 2
• A Study to Observe the Causes and Treatment of Anemia in Critically Ill ChildrenCompletedNCT00211055
• A Study of Patients Treated With Erythropoietin Receptor Agonists for Anemia Who Developed Anti-erythropoietin AntibodiesWithdrawnNCT00210977
• A Phase II Study to Assess Changes in Physical Function in Elderly Patients With Chronic AnemiaTerminatedNCT00210795Phase 2
• Alternate Dosing - Initiation of Every 2 Week Epoetin Alfa (PROCRIT) in the Treatment of Anemia.CompletedNCT00210743Phase 2
• The Duration StudyTerminatedNCT00210730Phase 3
• Early and Standard Intervention With 120,000 Units of PROCRIT (Epoetin Alfa) Every Three Weeks in Patients Receiving ChemotherapyCompletedNCT00210600Phase 2
• An Efficacy and Safety Study for Epoetin Alfa (PROCRIT) in Cancer Patients Not Receiving Chemotherapy or RadiationCompletedNCT00210587Phase 3
• Research Into the Treatment of Anemia for Critically Ill Patients Admitted to Intensive Care Units (ICU)CompletedNCT00091910Phase 3
• Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or RadiotherapyTerminatedNCT00083486Phase 3
• Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or RadiotherapyTerminatedNCT00083434Phase 3